In preparation for the upcoming pharmaceutical clinical trial of RP101, Redwood Pharma AB (publ) has retained Associate Professor Gerhard Garhöfer of the Medical University of Vienna as a medical advisor. Professor Garhöfer is a leading expert in ophthalmology in Europe and has extensive experience in treating patients with Dry Eye Disease.
Professor Garhöfer is currently researching within ophthalmology, ocular pharmacology and diagnostics at the Medical University of Vienna, Austria. He has many years of experience working with clinical trials, regulatory issues with the European Medicines Agency (EMA), pharmaceutical firms and academic institutions. Over the past 10 years Professor Garhöfer has focused his clinical research and development within Dry Eye Disease. As Redwood Pharma begins planning for the clinical trial, professor Garhöfer’s experience and breadth of knowledge will strengthen the Company’s medical expertise. His knowledge within ophthalmology will serve Redwood Pharma well in the evaluation of new pharmaceutical projects and technologies to acquire or in-license.
“Professor Gerhard Garhöfer’s comprehensive knowledge of the area of Dry Eye Disease affords us a unique opportunity to best plan for and execute our clinical trial. We are honored and happy that he has elected to join our team as an advisor and welcome him to Redwood Pharma”, says CEO Martin Vidaeus.
For more information:
Martin Vidaeus, CEO Redwood Pharma AB (publ.)
Tel: +46 (0) 70 232 29 29
E-mail: martin.vidaeus@redwoodpharma.se
This information is information that Redwood Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at February 13, 2017.
About Redwood Pharma
Redwood Pharma develops ophthalmic products for unmet medical needs. The Company’s first project is the development of drug candidate RP101 with a known active substance against chronic dry eye in postmenopausal women who have moderate to severe symptoms. With the drug delivery platform IntelliGel® the release of active substances is controlled. Through the use of IntelliGel®, Redwood Pharma can also improve dosing of other established drugs. Redwood Pharma’s strength lies in formulation and early clinical development. Revenues will be generated through licensing agreements with pharmaceutical companies that have capabilities to manufacture and sell commercial products worldwide.
Redwood Pharma AB (publ.) is listed on AktieTorget, a Swedish Multilateral Trading Facility (Ticker: REDW.ST, ISIN: SE008294789).
For more information visit: www.redwoodpharma.com